Endothelial integrity is mandatory for physiologic organ function; however, endothelium dysfunction can be caused by systemic inflammation, occurring during sepsis or organ rejection after transplantation. This article will address our current understanding of endothelial involvement in organ transplantation and rejection. Overall, more detailed studies focusing on the endothelial modulation after organ transplantation would be necessary to investigate the role of endothelium activation during organ rejection.
WolinskyH. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res. 1980;47(3):301–311.
2.
CinesDBPollakESBuckCA. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527–3561.
3.
GrossPLAirdWC. The endothelium and thrombosis. Semin Thromb Hemost. 2000;26(5):463–478.
4.
AirdWC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001;29(suppl 7):S28–S35.
5.
IngulliE. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010;25(1):61–74.
BevilacquaMPPoberJSMajeauGRFiersWCotranRSGimbroneMAJr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986;83(12):4533–4537.
8.
CinesDBPollakESBuckCA. Endothelial cells in physiology and in pathophysiology of vascular disorders. Blood. 1998;91(10):3527–3561.
9.
JinRCVoetschBLoscalzoJ. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005;12(3):247–258.
10.
WanecekMWeitzbergERudehillAOldnerA.The endothelin system in septic and endotoxin shock. Eur J Pharmacol. 2000;407(1-2):1–15
WakamotoSFujiharaMTakahashiD. Enhancement of endothelial permeability by coculture with peripheral blood mononuclear cells in the presence of HLA class II antibody that was associated with transfusion-related acute lung injury. Transfusion. 2010;51(5):993–1001.
Ait-OufellaHMauryELehouxSGuidetBOffenstadtG. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med. 2010;36(8):1286–1298.
15.
Santiago-DelpinEA. The endothelium and early immune activation: new perspective and interactions. Transplant Proc. 2004;36(6):1709–1713.
16.
FerroTJGertzbergNSeldenLNeumannPJohnsonA. Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. Am J Physiol. 1997;272(5 pt 1):L979–L988.
PatzeltJLangerHF. Platelets in angiogenesis. Curr Vasc Pharmacol. 2012;10(5):570–577.
19.
InoueTCroceKMorookaTSakumaMNodeKSimonDI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057–1066.
20.
BombeliTSchwartzBRHarlanJM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood. 1999;93(11):3831–3838.
21.
BombeliTKarsanATaitJFHarlanJM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997;89(7):2429–2442.
22.
BombeliTMuellerMHaeberliA. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997;77(3):408–423.
23.
McCuskeyRSUrbaschekRUrbaschekB. The microcirculation during endotoxemia. Cardiovasc Res. 1996;32(4):752–763.
24.
AikawaRKomuroIYamazakiT. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest. 1997;100(7):1813–1821.
25.
BaeuerlePAHenkelT. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141–179.
26.
AndrewPJMayerB. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43(3):521–531.
27.
PaulusPJenneweinCZacharowskiK. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?Biomarkers. 2011;16(suppl 1):S11–S21.
28.
ClausRABockmeyerCLSossdorfMLöscheW. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?Curr Mol Med. 2010;10(2):236–248.
29.
MossMGillespieMKAckersonLMooreFAMooreEEParsonsPE. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. Crit Care Med. 1996;24(11):1782–1786.
30.
MammotoTParikhSMMammotoA. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem. 2007;282(33):23910–23918.
31.
FiedlerUReissYScharpfeneckerM. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12(2):235–239.
32.
BechardDMeigninVScherpereelA. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37(5):417–425.
33.
SarrazinSAdamELyonM. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25–37.
34.
WitzIP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008;27(1):19–30.
35.
SiemiatkowskiARogowskiFWereszczyńska-SiemiatkowskaUMalinowskaLBorkowskiJ. Soluble selectin profiles associated with severe trauma. Arch Immunol Ther Exp (Warsz). 2001;49(4):317–324.
36.
CummingsCJSesslerCNBeallLD. Soluble E-selectin levels in sepsis and critical illness. Correlation with infection and hemodynamic dysfunction. Am J Respir Crit Care Med. 1997;156(2 pt 1):431–437.
37.
RaoRMYangLGarcia-CardenaGLuscinskasFW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res. 2007;101(3):234–247.
38.
MarasciuloFLMontagnaniMPotenzaMA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem. 2006;13(14):1655–1665.
39.
SchuetzPStolzDMuellerB. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis. 2008;8:22.
40.
DvorakHFBrownLFDetmarMDvorakAM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–1039.
41.
van der FlierMvan LeeuwenHJvan KesselKPKimpenJLHoepelmanAIGeelenSP. Plasma vascular endothelial growth factor in severe sepsis. Shock. 2005;23(1):35–38.
42.
GaengelKGenovéGArmulikABetsholtzC. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29(5):630–638.
MadoiwaSNunomiyaSOnoT. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84(5):398–405.
45.
DeitcherSREisenbergPR. Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia. Chest. 1993;103(4):1107–1112.
46.
BluestoneJAAuchinclossHNepomGTRotrosenDSt ClairEWTurkaLA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010;10(11):797–803.
47.
ChristieJDEdwardsLBKucheryavayaAY. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult lung and heart-lung transplant report-2011. Heart Lung Transplant. 2011;30(10):1104–1122.
48.
ChristieJDEdwardsLBKucheryavayaAY. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant. 2010;29(10):1104–1118.
49.
Sánchez-FueyoAStromTB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology. 2011;140(1):51–64.
50.
AfzaliBLechlerRIHernandez-FuentesMP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens. 2007;69(6):545–556.
51.
SinghNPirschJSamaniegoM. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev. 2009;23(1):34–46.
52.
IngulliE. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010;25(1):61–74.
53.
SafiniaNAfzaliBAtalarKLombardiGLechlerRI. T-cell alloimmunity and chronic allograft dysfunction. Kidney Int Suppl. 2010;119:S2–S12.
54.
MontecalvoAShufeskyWJStolzDB. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol. 2008;180(5):3081–3090.
55.
BirnbaumLMLipmanMParaskevasS. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009;4(4):860–865.
56.
AzimzadehAMLeesJRDingYBrombergJS. Immunobiology of transplantation: impact on targets for large and small molecules. Clin Pharmacol Ther. 2011;90(2):229–242.
57.
MitchellPAfzaliBLombardiGLechlerRI. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant. 2009;14(4):326–331.
58.
BattagliaM. Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go?Transpl Int. 2010;23(8):761–770.
59.
MollSPascualM. Humoral rejection of organ allografts. Am J Transplant. 2005;5(11):2611–2618.
60.
ColvinRBHirohashiTFarrisABMinneiFCollinsABSmithRN. Emerging role of B cells in chronic allograft dysfunction. Kidney Int Suppl. 2010;119:S13–S17.
61.
RodriguezERSkojecDVTanCD. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5(11):2778–2785.
62.
NathDSBashaHIMohanakumarT. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant. 2010;15(1):16–20.
63.
SeetharamATiriveedhiVMohanakumarT. Alloimmunity and autoimmunity in chronic rejection. Curr Opin Organ Transplant. 2010;15(4):531–536.
64.
MillingtonTMMadsenJC. Innate immunity and cardiac allograft rejection. Kidney Int Suppl. 2010;119:S18–S21.
65.
GoldsteinDR. Inflammation and transplantation tolerance. Semin Immunopathol. 2011;33(2):111–115.
66.
DupontPJManuelOPascualM. Infection and chronic allograft dysfunction. Kidney Int Suppl. 2010;119:S47–S53.
67.
ScollettaSBiagioliB. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed Pharmacother. 2010;64(3):203–237.
68.
TrpkovKCampbellPPazderkaFCockfieldSSolezKHalloranPF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation. 1996;61(11):1586–1592.
69.
HalloranPFWadgymarARitchieSFalkJSolezKSrinivasaNS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990;49(1):85–91.
70.
ValantineHA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant “atheroma”. Transplantation. 2003;76(6):891–899.
MachFSchönbeckUSukhovaGK. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94(5):1931–1936.
73.
ShimizuKMitchellRN. The role of chemokines in transplant graft arterial disease. Arterioscler Thromb Vasc Biol. 2008;28(11):1937–1949.
74.
ZhaoDXHuYMillerGGLusterADMitchellRNLibbyP.Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol. 2002;169(3):1556–1560.
HancockWWGaoWCsizmadiaVFaiaKLShemmeriNLusterAD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med. 2001;193(8):975–890.
77.
CrescioliCBuonamanoAScollettaS. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation. 2009;87(2):249–255.
78.
RotondiMNettiGSLazzeriE. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int. 2010;23(5):465–475.
79.
ManesTDPoberJSKlugerMS. Endothelial cell-T lymphocyte interactions: IP[corrected]-10 stimulates rapid transendothelial migration of human effort but not central memory CD4+ T cells. Requirements for shear stress and adhesion molecules. Transplantation. 2006;82(suppl 1):S9–S14.
80.
KhayyamianSHutloffABüchnerK. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A. 2002;99(9):6198–6203.
81.
RoseML. Endothelial cells as antigen-presenting cells: role in human transplant rejection. Cell Mol Life Sci. 1998;54(9):965–978.
BartelDP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
84.
BonauerACarmonaGIwasakiM. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710–1713.
85.
CharreauB. Molecular regulation of endothelial cell activation: novel mechanisms and emerging targets. Curr Opin Organ Transplant. 2011;16(2):207–213.
86.
Le BrasASamsonCTrentiniM. VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One. 2010;5(8):e12156.
KrupnickASGelmanAEBarchetW. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol. 2005;175(10):6265–6270.
89.
KunterUDanielSArveloMB. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Kidney Int. 2005;68(4):1520–1532.
90.
KoopmansMKremer HovingaICBaeldeHJde HeerEBruijnJABajemaIM. Endothelial chimerism in transplantation: Looking for needles in a haystack. Transplantation. 2006;82(suppl 1):S25–S29.
91.
PicasciaAGrimaldiVZulloA. Current concepts in histocompatibility during heart transplant. Exp Clin Transplant. 2012;10(3):209–218.
92.
CrudeleVPicasciaAInfanteTGrimaldiVMaielloCNapoliC. Repeated immune and non immune insults to the graft after heart transplantation. Immunol Lett. 2011;141(1):18–27.
